Zevalin: payments to doctors
Payments that named Zevalin as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $68K
- Providers
- 413
- Transactions
- 643
- Average per transaction
- $105
The per-transaction average — $105 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 413 providers the average total is $164, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Aurobindo Pharma USA, Inc. | $65,779 | 97.1% |
| Spectrum Pharmaceuticals Inc. | $1,503 | 2.2% |
| Acrotech Biopharma LLC | $482 | 0.7% |